You can buy or sell VIVUS and other stocks, options, ETFs, and crypto commission-free!
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Read More Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
52 Week High
52 Week Low
Yahoo FinanceMar 14
VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction
CAMPBELL, CA / ACCESSWIRE / March 14, 2019 / VIVUS, Inc. (NASDAQ: VVUS; the "Company"), a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile dysfunction (ED). The product will be marketed in the Russian Federation under the brand name RAZATUS. "The approval of avanafil in the Russian Federation adds to the growing list of territories in which the product is now available for...
NASDAQ:VVUS - Stock Price, News, & Analysis for VIVUS
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high ch...
Simply Wall StMar 8
If You Had Bought VIVUS (NASDAQ:VVUS) Stock Five Years Ago, You’d Be Sitting On A 92% Loss, Today
VIVUS, Inc. (NASDAQ:VVUS) shareholders will doubtless be very grateful to see the share price up 58% in the last quarter. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. Like a ship taking on water, the share price has sunk 92% in that time. It’s true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The fundamental business performance will ultimately determine if the turnaro...
Expected May 7, After Hours